Feedback
Settings

Settings

Goto Application

3,609 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61M AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 361
1.WO/2021/181261LACTOFERRIN FOR ORAL INHALATION USE FOR THE TREATMENT OF A DISEASE CAUSED BY A SARS-CORONA VIRUS
WO - 16.09.2021
Int.Class A61K 38/40
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
40Transferrins, e.g. lactoferrins, ovotransferrins
 Appl.No PCT/IB2021/051941 Applicant SOFAR S.P.A. Inventor BIFFI, Andrea
The present invention relates to a composition comprising lactoferrin for inhalation use in the treatment of viral infections of the respiratory system, and related symptoms or disorders, caused by a SARS- coronavirus (e.g. COVID-19 disease). In addition, the present invention relates to a device for the administration - through the inhalation route - of said composition comprising lactoferrin and the use thereof in said methods for the treatment of viral infections.
2.20250161334Method Of Treating, Reducing, Or Alleviating A Medical Condition In A Patient
US - 22.05.2025
Int.Class A61K 31/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
 Appl.No 19033071 Applicant Gholam A. Peyman Inventor Gholam A. Peyman

A method of treating, reducing, or alleviating a medical condition in a patient includes administering to a patient in need thereof, a pharmaceutical composition comprising one or more antiviral medications together with an anti-vascular endothelial growth factor (anti-VEGF) medication and a rho-associated protein kinase (ROCK) inhibitor, the patient having at least one of a respiratory tract inflammatory disease, a central nervous system inflammatory disease, and vasculitis, the one or more antiviral medications preventing an attachment of viruses to cell walls, blocking a penetration of the viruses into cells, and/or inhibiting virus replication by damaging nucleic acids of the viruses, and the anti-VEGF medication and ROCK inhibitor treating an exhausted cellular immune response and inflammation of the patient. In one or more other embodiments, the pharmaceutical composition comprises one or more antiviral medications together with at least one of: (i) cannabidiol (CBD), (ii) linoleic acid, (iii) catechin, and (iv) metformin.

3.20230338520Method of treating, reducing, or alleviating a medical condition in a patient
US - 26.10.2023
Int.Class A61K 39/39
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
39characterised by the immunostimulating additives, e.g. chemical adjuvants
 Appl.No 18216531 Applicant Gholam A. Peyman Inventor Gholam A. Peyman

A method for producing an immunogenic composition includes growing viruses, bacteria, fungi, parasites, or tumor cells on a cell culture or other appropriate medium; harvesting the viruses, bacteria, fungi, parasites, or tumor cells; killing the viruses, bacteria, fungi, parasites, or tumor cells with one or more medications that damage the RNA and/or the DNA of the viruses, bacteria, fungi, parasites, or tumor cells; separating the dead viruses, bacteria, fungi, parasites, or tumor cells; depending on the type of organism, adding antivirals, antibacterials, antifungals, antiparasitics, and/or anti-neoplastic medications at non-toxic concentrations to the dead viruses, bacteria, fungi, parasites, or tumor cells so as to form an immunogenic composition; and administering the immunogenic composition and an adjuvant to a patient in need thereof.

4.20210252033N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO
US - 19.08.2021
Int.Class A61K 31/7068
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7068having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
 Appl.No 17170172 Applicant Emory University Inventor George R. PAINTER

This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of human coronavirus 2019-nCoV.

5.20250064844N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO
US - 27.02.2025
Int.Class A61K 31/7068
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7068having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
 Appl.No 18940253 Applicant Emory University Inventor George R. PAINTER

This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of human coronavirus 2019-nCoV.

6.WO/2021/243372CLOSED-LOOP ANTIMICROBIAL PHOTO-PLASMAPHERESIS
WO - 02.12.2021
Int.Class A61M 1/36
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
1Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation
 Appl.No PCT/US2021/070633 Applicant BAYLOR COLLEGE OF MEDICINE Inventor SZIGETI, Reka
The present disclosure concerns systems and methods related to the treatment, prevention, delay of onset, or reduction of severity of a microbial infection in an individual, including closed-loop plasmapheresis and extracorporeal light irradiation of the plasma of the individual. The systems and methods further relate to irradiation of the plasma of the individual with UV and/or visible light, optionally in the presence of a photosensitizer. The systems and methods further relate to light irradiation inactivation of microbial particles in the plasma taken from the individual. The systems and methods further relate to the optional filtration of microbial particles from UV light-treated plasma. The systems and methods further relate to reinfusion of the UV light-treated, optionally filtered, plasma back into the individual. The systems and methods further relate to treating, preventing, delaying onset of, or reducing in severity a viral infection, particularly a viral infection caused by a Coronaviridae family virus, at least including SARS-CoV-2. The systems and methods are further configured to reduce viral load and/or lymphocyte reinfection rate in the individual.
7.WO/2024/046582PHARMACEUTICAL DRY POWDER COMPOSITION AND METHODS FOR TREATING RESPIRATORY TRACT INFECTIONS
WO - 07.03.2024
Int.Class A61K 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
 Appl.No PCT/EP2022/074500 Applicant LIITA CARE APS Inventor MINAMOTO, Suzana Erico Tanni
The present invention provides a pharmaceutical dry powder composition for use in treating, preventing and/or ameliorating viral infection in airways of a mammal, such as a human subject, said composition comprising micronized sodium salt as the main component and primary therapeutic agent. The present invention further provides a pharmaceutical composition for use in treating and/or ameliorating cough. The subject to be treated with the pharmaceutical composition may be infected with SARS-CoV-2 and/or diagnosed with COVID-19 infection. The pharmaceutical composition is administered by dry powder inhalation.
8.2022476747PHARMACEUTICAL DRY POWDER COMPOSITION AND METHODS FOR TREATING RESPIRATORY TRACT INFECTIONS
AU - 07.03.2024
Int.Class A61K 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
 Appl.No 2022476747 Applicant LIITA CARE APS Inventor MINAMOTO, Suzana Erico Tanni
9.20230158259PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, AMELIORATING OR PREVENTING MICROBIAL INFECTIONS
US - 25.05.2023
Int.Class A61M 15/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
15Inhalators
08Inhaling devices inserted into the nose
 Appl.No 17921097 Applicant TOPELIA AUST LIMITED Inventor Thomas Julius BORODY

In alternative embodiments, provided are products of manufacture fabricated or manufactured as medical devices such as an inhaler, an ionizer, an asthma “puffer-like” device, a nebulizer or a nasal spray device, a respirator or a ventilator, a warm or a hot air delivery device, and/or a CPAP (continuous positive air pressure) device (for example, for managing or treating sleep apnea) or equivalent, for delivering one or a combination of medications or drugs, and optionally also warm or hot air, and optionally also ionized air. Products of manufacture are used for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a microbial infection, such as bacterial and viral infections, including the common respiratory viruses such as influenza virus, respiratory syncytial virus, picornavirus, parainfluenza virus, adenovirus, rhinovirus, human metapneumovirus, hantaviruses, enterovirus, a coronavirus infection, or a COVID-19 or a 2019-nCoV (or so-called Wuhan coronavirus) infection, or an infection caused by a virus in the subfamily Orthocoronavirinae, or a virus in the family Coronaviridae, or a virus in the order Nidovirales. In alternative embodiments, products of manufacture as provided herein administer combinations, or cocktails, of a drug or drugs by inhalation, for example, by use of aerosol, mist, liquid or powder formulations for inhalation.

10.2021261049Products of manufacture and methods for treating, ameliorating or preventing microbial infections
AU - 28.10.2021
Int.Class A61K 31/4706
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
47064-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
 Appl.No 2021261049 Applicant Topelia Aust Limited Inventor BORODY, Thomas Julius
Provided are products of manufacture fabricated or manufactured as medical devices such as an inhaler, an ionizer, an asthma "puffer-like" device, a nebulizer or a nasal spray device, a respirator or a ventilator, a warm or a hot air delivery device, and/or a CPAP (continuous positive air pressure) device or equivalent, for delivering one or a combination of medications or drugs, and optionally also warm or hot air, and optionally also ionized air. Said drug combinations include various combinations of antivirals, antiparasitics, antibacterials, and adjunct therapeutics, including at least one of Hydroxychloroquine, Chloroquine, Oseltamivir, Lopinavir, Ritonavir, Ribavirin, Favipiravir, Remdesivir, Azithromycin, Ivermectin, Doxycycline, and Opaganib or combinations thereof. Products of manufacture are used for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a microbial infection, such as bacterial and viral infections, including the common respiratory viruses such as influenza vims, respiratory syncytial vims, picornavims, parainfluenza vims, adenovims, rhinovims, human metapneumovims, hantavimses, enterovims, a coronavims infection, or a COVID-19 or a 2019-nCoV (SARS-CoV-2) infection, or an infection caused by a vims in the subfamily Orthocoronavirinae, or a vims in the family Coronaviridae, or a vims in the order Nidovirales. In alternative embodiments, products of manufacture as provided herein administer combinations, or cocktails, of a dmg or dmgs by inhalation, for example, by use of aerosol, mist, liquid or powder formulations for inhalation.
# -